Blar i forfatter "Forveille, Sabrina"

Viser treff 1-3 av 3

    • Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals 

      Zhou, Heng; Mondragón, Laura; Xie, Wei; Mauseth, Brynjar; Leduc, Marion; Sauvat, Allan; Gomes-da-Silva, Lígia C.; Forveille, Sabrina; Iribarren, Kristina; Souquere, Sylvie; Bezu, Lucillia; Liu, Peng; Zhao, Liwei; Zitvogel, Laurence; Sveinbjørnsson, Baldur; Eksteen, Jacobus Johannes; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-23)
      Abstract Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 ...

    • The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization 

      Zhou, Heng; Forveille, Sabrina; Sauvat, Allan; Sica, Valentina; Izzo, Valentina; Durand, Sylvère; Müller, Kevin; Liu, Peng; Zitvogel, Laurence; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-09-10)
      LTX-315 has been developed as an amphipathic cationic peptide that kills cancer cells. Here, we investigated the putative involvement of mitochondria in the cytotoxic action of LTX-315. Subcellular fractionation of LTX-315-treated cells, followed by mass spectrometric quantification, revealed that the agent was enriched in mitochondria. LTX-315 caused an immediate arrest of mitochondrial ...

    • The oncolytic peptide LTX-315 triggers immunogenic cell death 

      Zhou, Heng; Forveille, Sabrina; Sauvat, Allan; Yamazaki, T; Senovilla, L; Ma, Y; Liu, Peng; Yang, H; Bezu, L; Müller, K; Zitvogel, Laurence; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-03-10)
      LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/ BAK1-regulated, caspase-independent necrosis. Based on the observation that intratumorally injected LTX-315 stimulates a strong T lymphocyte-mediated anticancer immune response, we investigated whether LTX-315 may elicit the hallmarks of immunogenic cell death (ICD), ...